The U.S. Food and Drug Administration (FDA) approved NEXIUM® delayed release capsules in children ages 12 to 17 for the short-term treatment of gastroesophageal reflux disease (GERD). NEXIUM was tested in adolescents ages 12 to 17 in a randomized, double-blind parallel group study in which a total of 149 patients, ages 12 to 17, with clinically diagnosed GERD were treated with either NEXIUM 20mg or NEXIUM 40 mg once a day for up to eight weeks. Reported side effects included headache,...
Read moreWhat is the right tool for 24/7 pain? Having the right tool for the job can mean the difference between being on a roller coaster of... Read more »
Last week Zogenix, Inc., a pharmaceutical company that develops products for treating central nervous system disorders and pain, announced... Read more »
Remember that game show called "Press Your Luck" where contestants would battle the game of chance in order to win money. Land on a... Read more »
If you take prescription opioid medications for your chronic pain, please read this alert.The FDA is advising patients and health care... Read more »
On March 10, 2011, King Pharmaceuticals, Inc., a subsidiary of Pfizer, Inc., voluntarily recalled all dosage forms of Embeda® (morphine... Read more »
Source: eOrthopod
This is part two of a study started in 1986. The doctors decided to extend the study to look at results five to 12 years after lateral retinacular... Read more »
What exactly is a "black box" warning?Simply put, it's the strongest warning that the U.S. Food and Drug Administration (FDA) can require on a... Read more »
Wondering what's new? It can be tough to keep up with new information on MyMigraineConnection -- ... new articles about Migraines, medications, ... Read more »
The U.S. Food and Drug Administration has approved the acid reflux drug Nexium for short-term use in children ages 1 to 11. The agency approved... Read more »
The U.S. Food and Drug Administration (FDA) has granted approval for Atomoxetine HCl--a generic version of the ADHD medication Strattera. The FDA... Read more »